Octagon Capital Advisors Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$903.6M
Q ending 2026-03-31
Prior quarter
$823.7M
Q ending 2025-12-31
Change
+9.7% QoQ · +74.8% YoY
Positions
29
reported holdings
Largest positions
All 29 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Dianthus Therapeutics Inc | DNTH | Shares | $163.4M | 1.9M |
| Cogent Biosciences Inc | COGT | Shares | $90.5M | 2.4M |
| Abivax Sa | ABVX | Shares | $75.4M | 677K |
| Alumis Inc | ALMS | Shares | $62.4M | 2.8M |
| Definium Therapeutics Inc | DFTX | Shares | $46.1M | 2.4M |
| Arrivent Biopharma Inc | AVBP | Shares | $45.5M | 2.0M |
| Taysha Gene Therapies Inc | TSHA | Shares | $39.6M | 8.9M |
| Kymera Therapeutics Inc | KYMR | Shares | $35.4M | 425K |
| Mirum Pharmaceuticals Inc | MIRM | Shares | $31.3M | 339K |
| Bioage Labs Inc | BIOA | Shares | $30.6M | 1.7M |
| Centessa Pharmaceuticals Plc | 260 | Shares | $29.8M | 750K |
| Kalvista Pharmaceuticals Inc | 4XC1 | Shares | $29.2M | 1.4M |
| Xenon Pharmaceuticals Inc | XENE | Shares | $28.5M | 490K |
| Terns Pharmaceuticals Inc | 430 | Shares | $27.9M | 530K |
| Ocular Therapeutix Inc | OCUL | Shares | $26.8M | 3.2M |
| Palisade Bio Inc | PALI | Shares | $18.0M | 10.3M |
| Trevi Therapeutics Inc | TRVI | Shares | $17.7M | 1.5M |
| Disc Medicine Inc | IRON | Shares | $17.3M | 270K |
| Aktis Oncology Inc | AKTS | Shares | $17.2M | 961K |
| Context Therapeutics Inc | CNTX | Shares | $13.8M | 5.3M |
| Precision Biosciences Inc | DTIL | Shares | $12.3M | 2.2M |
| Dbv Technologies S A | DBVT | Shares | $12.0M | 574K |
| Unicycive Therapeutics Inc | UNCY | Shares | $6.6M | 1.0M |
| Bridgebio Oncology Therapeut | BBOT | Shares | $6.4M | 719K |
| Lexeo Therapeutics Inc | LXEO | Shares | $6.3M | 1.1M |
| Pharvaris N V | Shares | $4.7M | 165K | |
| Perspective Therapeutics Inc | CATX | Shares | $3.3M | 792K |
| Evommune Inc | EVMN | Shares | $3.3M | 143K |
| Gossamer Bio Inc | GOSS | Shares | $2.5M | 7.8M |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.